During her time at Editas Medicine, Cynthia Collins was involved in significant stock holdings. By 2020, she held stock options that could yield substantial returns. Despite the challenges faced, her decision-making regarding stock options and awards illustrated her strategic involvement...

During her time at Editas Medicine, Cynthia Collins was involved in significant stock holdings. By 2020, she held stock options that could yield substantial returns. Despite the challenges faced, her decision-making regarding stock options and awards illustrated her strategic involvement in raising the company’s profile. Her equity in Editas peaked before she stepped down as CEO, signifying a pivotal point in her financial journey. Upon her departure, she held vested stock worth about $1,025,091 based on past grants, underscoring a strong belief in the company's potential even as she transitioned out. This wealth in stock options reflected her commitment to Editas and belief in its vision, although her early departure and the forfeiture of unvested portions marked a turning point in her financial landscape.